Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical GroupFRA:S2P -2.86%86 Days Inventory is 144.71 as of Dec. 2025, which is 42% above its 10-year median of 101.57. GuruFocus rates FRA:S2P with a GF Score™ of 86/100 and a GF Value™ of €1.15 (Modestly Overvalued). Among 921 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks better than 56.89% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Simcere Pharmaceutical Group's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.26.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Simcere Pharmaceutical Group's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.14.
Simcere Pharmaceutical Group (FRA:S2P) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Simcere Pharmaceutical Group's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Simcere Pharmaceutical Group's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Simcere Pharmaceutical Group Days Inventory Related Terms
Simcere Pharmaceutical Group Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Days Inventory distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (FRA:S2P) has a Days Inventory of 144.71 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Simcere Pharmaceutical Group and its competitors. This is 42% above median its historical median of 101.57. Over the past decade, Simcere Pharmaceutical Group's Days Inventory has ranged from 77.35 to 170.35. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #397 out of 921 companies in the Drug Manufacturers industry, placing it in the top 43.1%.
Is Simcere Pharmaceutical Group's Days Inventory too high?
Simcere Pharmaceutical Group's current Days Inventory of 144.71 is 42% above median its 10-year median of 101.57. Over the past 10 years, this metric has ranged from a low of 77.35 to a high of 170.35. The Drug Manufacturers industry median Days Inventory is 164.48. Simcere Pharmaceutical Group's value of 144.71 is 12% below this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #397 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #397 out of 921 companies for Days Inventory. This puts Simcere Pharmaceutical Group in the upper half of its industry. The industry median Days Inventory is 164.48. Simcere Pharmaceutical Group's value of 144.71 is 12% below this benchmark. Historically, Simcere Pharmaceutical Group's own Days Inventory has ranged from 77.35 to 170.35 over the past decade. While the company's 10-year median is 101.57 vs. the industry median of 164.48, Simcere Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current Days Inventory of 144.71 is 12% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current Days Inventory is 144.71, which is 42% above median its own 10-year median of 101.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (FRA:S2P) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.15, compared to a current price of €1.36 — trading 18.3% above its estimated fair value. The current Days Inventory is 144.71, which is 42% above median its 10-year median of 101.57 and 12% below the Drug Manufacturers industry median of 164.48. Simcere Pharmaceutical Group's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Simcere Pharmaceutical Group (FRA:S2P), the current Days Inventory is 144.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (FRA:S2P) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.36 is trading 18.3% above its estimated GF Value™ of €1.15.
GuruFocus considers Simcere Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for FRA:S2P:
Days Inventory: 144.71 (42% above median its 10-year median of 101.57)
GF Value™: €1.15 vs. price of €1.36 (18.3% above fair value)
Industry Position: 12% below the Drug Manufacturers median (#397 of 921)
No single metric tells the full story. See the FRA:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
86GF Score
Get the complete analysis for FRA:S2P
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S2P has been successfully added to your 
